Study evaluates obicetrapib, a novel cholesteryl ester transfer protein (CETP) inhibitor, as an adjunct to diet and maximally tolerated lipid-lowering therapy Company is expected to complete enrollment in 2022 and announce data in the first quarter of 2024 NAARDEN, Netherlands–(BUSINESS […]